Sentences with phrase «turing pharmaceuticals»

* Turing Pharmaceuticals, the drug company once led by disgraced pharma bro Martin Shkreli, has been accused of retaliation following the alleged sexual assault of its chief commercial officer at the hands of its interim chief financial officer.

Months later in December, news reports reveal that Martin Shkreli, the 32 - year - old founder of Turing Pharmaceuticals, who has been accused of serious price gauging, bought the album for about $ 2 million.

It's been an insane week for MOBAs, as it turns out that Turing Pharmaceuticals CEO Martin Shrekli (the guy who bought an AIDS drug and raised the price by over 5,000 %) recently set up an e-sports organisation with its fingers in both League of Legends and Dota 2.

Though Shkreli is best known for hiking the price of a decades - old drug by 5,000 percent when he led Turing Pharmaceuticals, this trial related to an entirely different matter: Ponzi - like fraud.

A few months ago, BBC News suggested that «Martin Shkreli, the 32 - year - old chief executive of Turing Pharmaceuticals, may be the most hated man in America right now.»

He went on to defend the price gouge, saying that his company, Turing Pharmaceuticals, needed to continue to profit and that anyone who really needed the drug would be able to afford it.

Scandals can pertain to large - scale corporate conduct involving the cooperation of many people (such as the Volkswagen emissions - falsification scandal), to an individual corporate decision (as when Turing Pharmaceuticals raised the price of one of its drugs from $ 13.50 to $ 750 per pill), or to illicit behaviour by an individual (such as a corporation's CEO).

The hedge fund founder and CEO of Turing Pharmaceuticals jacked up the price of a popular HIV drug from $ 13.50 per pill to roughly $ 750.

Turing Pharmaceuticals AG, the drugmaker that raised the price of an anti-infective drug Daraprim by more than 5,000 percent, suggested that it won't cut the drug's list price, instead offering to negotiate discounts with hospitals.

It was 2015 when Martin Shkreli, then CEO of Turing Pharmaceuticals and the notorious «pharma bro,» jacked up the cost of the lifesaving drug Daraprim by 5,000 percent.

In response to the outrage over what appears to be blatant price gouging on the part of Turing Pharmaceuticals, the company's founder and CEO Martin

Turing Pharmaceuticals CEO Martin Shkreli is now stating that he wishes he'd raised the price on the AIDS drug Daraprim by more than the 5000 % that made him the object of scorn worldwide.

Martin Shkreli, the chief executive of Turing Pharmaceuticals, explains the increase in drug prices in a CNBC interview.

In response to the outrage over what appears to be blatant price gouging on the part of Turing Pharmaceuticals, the company's founder and CEO Martin Shkreli has announced that Turing will be lowering the price of the drug Daraprim after raising it from $ 13.50 to $ 750 per tablet overnight.

When he learned he was under criminal investigation by the FBI, Turing Pharmaceuticals CEO Martin Shkreli could have kept a low profile and gone to the Caribbean.

Martin Shkreli is the founder and chief executive of Turing Pharmaceuticals, which raised the price of the drug Daraprim to $ 750 a tablet from $ 13.50.

The spectacle that Shkreli created around himself and his company Turing Pharmaceuticals since late summer, even as the criminal probe proceeded, raised the question of whether he had any idea of the risk he was running — or whether his conduct was part of a plan to beat the rap in Brooklyn federal court and generate business.

The drug, called Daraprim, was acquired in August by Turing Pharmaceuticals, a start - up run by a former hedge fund manager.

Turing Pharmaceuticals of New York bought the drug from Impax Laboratories in August for $ 55 million and raised the price.

Turing Pharmaceuticals was warned by New York's attorney general that the distribution network for a rarely used drug, whose 55-fold overnight price hike drew widespread criticism, may violate antitrust laws.

But recent high - profile price hikes by Mylan NV (MYL.O), Turing Pharmaceuticals and Valeant Pharmaceuticals International Inc (VRX.TO) have raised the ire of consumers and lawmakers.

It is alleged that what brought Valeant down was not its own activities but the actions of Martin Shkreli, a former hedge fund manager who is now chief executive officer of Turing Pharmaceuticals.

His company, Turing Pharmaceuticals AG, bought the drug, moved it to a closed distribution system and instantly drove the price into the stratosphere.

After leaving Retrophin, Shkreli founded a biopharmaceutical company called Turing Pharmaceuticals, where he serves as the Executive Chairman.

Long before Martin Shkreli was arrested in New York Thursday morning on securities fraud charges, the outspoken, 32 - year - old chief executive officer of Turing Pharmaceuticals AG had made himself famous.

Turing Pharmaceuticals LLC CEO Martin Shkreli discusses why the company increased the price of a drug from $ 13.50 to $ 750 a tablet.

Martin Shkreli, the Turing Pharmaceuticals LLC executive who drew criticism in August over a dramatic jump in a prescription drug price, made headlines Thursday for a different kind of price increase: a seven-fold surge in the shares of a microcap pharmaceutical company.

February 2015: Launches new company, Turing Pharmaceuticals, which acquires an old drug and jacks up their prices.

If not Mylan's Bresch, it's Turing Pharmaceuticals» Martin Shkreli, who jacked up the price of Daraprim — used to treat life - threatening infections — from $ 13.50 to $ 750 a pill.

Tilles» career started at Merrill Lynch in 1985, and worked with several other firms before coming to Turing Pharmaceuticals.

World - class asshole Martin Shkreli found himself in the news yet again when he resigned his position as CEO at Turing Pharmaceuticals.

We wish to thank Martin for helping us build Turing Pharmaceuticals into the dynamic research focused company it is today, and wish him the best in his future endeavors.

The judge said that the punishment for the founder of Turing Pharmaceuticals is not for jacking up the price of a lifesaving drug, nor for his abrasive behavior.

Nevertheless, Shkreli is now in custody, and Turing Pharmaceuticals is taking measures to continue operations following his resignation.

But you probably know Mr. Shkreli from his company Turing Pharmaceuticals's outrageous increasing of prices on a drug that helps people with compromised immune systems fight parasitic infections.

U.S. drugmaker Turing Pharmaceuticals, led at the time by hedge fund manager Martin Shkreli, caused outrage last year by raising the U.S. price of Daraprim, an old anti-infective drug, by more than 5,000 % to $ 750 a pill.

Startup Turing Pharmaceuticals acquired Daraprim, a drug used to treat toxoplasmosis, in August.

Before Turing Pharmaceuticals, Shkreli founded and served as CEO of biotech company Retrophin from 2011 until September 2014.

Last month, Martin Shkreli, the «bro» - ish CEO of Turing Pharmaceuticals, managed to become «the most hated man in America.»

Forgetting that simple rhyme may have been the undoing of Martin Shkreli, the biotech short - seller turned controversial CEO of Turing Pharmaceuticals who was arrested Thursday.

The 32 - year - old CEO of Turing Pharmaceuticals became a target of widespread ire in September when he boosted the price of the toxoplasmosis treatment Daraprim by over 5,000 % after acquiring the drug in August.

While exorbitant drug price hikes by Martin Shkreli's Turing Pharmaceuticals and Valeant have sparked outrage in Washington and tanked the stock prices of much of the pharmaceutical sector in the last six months, there's growing evidence that the controversy may be more smoke than fire.

Turing Pharmaceuticals, which raised the price of a drug 5,500 % practically overnight says it will now lower its price following an intense backlash from the media, medical profession and the general public.

Turing Pharmaceuticals founder Martin Shkreli confirmed the price cut to NBC News on Tuesday but did not say how much the company would reduce the cost of Daraprim.

The Republican majority in the oversight committee plan to invite Turing Pharmaceuticals CEO Martin Shkreli to testify, and the Democratic minority plans to invite Pearson, a Democratic staffer told Business Insider via email.

Notably missing from the panel of witnesses — which focused mainly on actions by Valeant and Turing Pharmaceuticals — were the companies that have done so.

If you haven't followed this story, you'll remember Shkreli from his fame two years ago, when his biotech firm, Turing Pharmaceuticals, acquired the patent to a drug used to treat malaria, cancer and aids, and jacked up the retail price by more than 5,000 percent.

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

Here's the response Turing Pharmaceuticals sent Business Insider in regards to the Senate Committee's letter:

In September, the pair sent a letter to Turing Pharmaceuticals CEO Martin Shkreli after he jacked up the price of Daraprim, a drug used to treat malaria and parasitic infections in patients with weakened immune systems, from $ 13.50 to $ 750 per pill.